Ignite Creation Date:
2024-05-06 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 2:25 PM
Study NCT ID:
NCT05253430
Status:
COMPLETED
Last Update Posted:
2022-02-23
First Post:
2022-01-13
Brief Title:
D1 vs D2 Lymphadenectomy in Gastric Cancer
Sponsor:
Fundación para la Investigación del Hospital Clínico de Valencia
Organization:
Fundación para la Investigación del Hospital Clínico de Valencia
Study Overview
Official Title:
Prognostic Implications of D1 vs D2 Lymphadenectomy in Gastric Cancer a Propensity Score Matched Analysis
Status:
COMPLETED
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a retrospective study with a propensity score-matched analysis in order to balance differences between patients with D1 and D2 lymphadenectomy for gastric cancerThe main aim is to analyse differences in the postoperative and oncological outcomes of patients with gastric cancer GC who underwent D1 and D2 gastrectomy
Detailed Description:
In this propensity score-matched analysis of 128 patients D2 lymphadenectomy improved long-term outcomes compared with D1 in patients with curative intent surgery for gastric cancer except for the group of patients older than 75 years and with early tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None